Myeloid malignancies, clonal dynamics, and TLs. (A) A swimmer diagram highlighting long-term follow-up of patients with chromosomal abnormalities and/or myeloid malignancies. (B) Differences of VAF of somatic mutations after the completion of danazol therapy compared to baseline in PPM1D, TERTp, U2AF1, and other genes (RUNX1, ASLX1, BCOR, GATA2, SETBP1, ZRSR2, ETV6, and PHF6). Positive values represent variants that expanded posttherapy, whereas negative values represent variants that decreased in size. Outliers in red represent a BCOR variant that highly expanded after danazol therapy but eventually decreased in size after drug discontinuation and a TERTp variant that decreased in size (supplemental Figure 6). (C) Clonal dynamics of TERTp, PPM1D (all exon 6 truncations), and U2AF1 p.Ser34Phe somatic mutations in available samples from therapy initiation. The time of danazol treatment is indicated in gray. Each line color represents a single patient. (D) Average ΔTL before and after danazol treatment on study. Mean and standard deviation are marked. (E) TL of lymphocytes measured using flow-FISH after the trial for patients for whom danazol was reinitiated (left panel) or who were continued off-therapy (right panel). BMT, bone marrow transplant; del, deletion; EB2, excess blasts 2; MLD, multilineage dysplasia; ΔTL, delta TL; VAF, variant allele frequency.